Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.

Anduril, the closely held technology startup that makes autonomous systems and weapons for the military, on Thursday announced plans to build a $1 billion factory in Columbus, Ohio. The company ...

Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient ...

Our 2025 plan includes scaling our new commercial strategy, advancing the Allurion Balloon through the FDA approval process, setting the company up for a profitable 2026, expanding our digital ...

Allurion Technologies shares rose after agreeing to a private placement with expected gross proceeds of $2.5 million that will extend its runway through early 2026. The stock was up 13% to $3.37 ...

Our 2025 plan includes scaling our new commercial strategy, advancing the Allurion Balloon through the FDA approval process, setting the company up for a profitable 2026, expanding our digital ...